| 引用本文:邹孟龙1，黄晓燕2，陈雅璐2，宁芯1.四君子汤为基本方治疗溃疡性结肠炎的Meta分析[J].世界中医药,2021,(24):. |
|
| 四君子汤为基本方治疗溃疡性结肠炎的Meta分析 |
| Meta Analysis of Sijunzi Decoction as the Basic Prescription in the Treatment of Ulcerative Colitis |
| 投稿时间：2020-07-27 |
| DOI：10.3969/j.issn.1673-7202.2021.24.010 |
| 中文关键词: 四君子汤 溃疡性结肠炎 Meta分析 系统评价 随机对照试验 肿瘤坏死因子α 白细胞介素-33 超氧化物歧化酶 |
| English Keywords:Sijunzi Decoction Ulcerative colitis Meta Analysis Systematic review Randomized controlled trial Tumor necrosis factor α Interleukin-33 Superoxide dismutase |
| 基金项目:国家自然科学基金项目（81460714）——端粒短缩介导上皮细胞凋亡参与溃疡性结肠炎相关癌变及四君子汤干预研究；广西创新驱动发展专项（桂科AA17202031)——健脾益气口服液的开发研究 |
|
| 摘要点击次数: 209 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：评估四君子汤为基本方的方药治疗溃疡性结肠炎（UC）的疗效。方法：检索7个医学常用数据库，收集四君子汤治疗UC的随机对照试验，时限均为建库至2020年3月，然后对数据进行整理和分析。结果：共纳入22项研究，包括1 862例患者。Meta分析显示：与常规西药治疗比较，四君子汤为基本方的方药能提高内镜疗效(OR=3.76,95%CI为2.83~5.00，P<0.000 01）、中医证候疗效(OR=3.08,95%CI为1.21~7.87，P=0.02）；改善血清肿瘤坏死因子α表达(MD=-5.21,95%CI为-6.86~-3.56,P<0.000 01）、血清白细胞介素-33表达（MD=-1.10,95%CI为-1.28~-0.92,P<0.000 01）、血清超氧化物歧化酶表达（MD=107.64,95%CI为84.14~131.14,P<0.000 01）以及降低不良反应发生率（OR=0.37,95%CI为0.15~0.94，P=0.04）。结论：四君子汤为基本方的方药治疗溃疡性结肠炎可显著提高临床疗效，改善血清炎症介质、超氧化物歧化酶表达，且安全性高。 |
| English Summary: |
| To evaluate the efficacy of Sijunzi Decoction in the treatment of ulcerative colitis(UC).Methods:A total of 7 commonly used medical databases were searched by computer，and the randomized controlled trials of Sijunzi Decoction in the treatment of UC were collected，all of which were built from March to March 2020，and then the data were collected and analyzed.Results:A total of 22 studies were included，including 1862 patients.The results of Meta analysis showed that compared with conventional Western medicine，the prescription with Sijunzi Decoction as the basic prescription could improve the curative effect of endoscope ［(OR=3.76,95%CI(2.83 to 5.00)，P<0.000 01］ and the curative effect of traditional Chinese medicine symptoms ［(OR=3.08,95%CI(1.21 to 7.87)，P=0.02］，improve the expression of serum tumor necrosis factor-α ［MD=-5.21,95%CI(-6.86 to -3.56)，P<0.000 01］，the expression of serum interleukin-33 ［MD=-1.10,95%CI(-1.28 to -0.92),P<0.000 01］，the expression of serum superoxide dismutase ［MD=107.64,95%CI(84.14 to 131.14)，P<0.000 01］，and reduce the incidence of adverse reactions ［(OR=0.37，95%CI(0.15 to 0.94)，P=0.04］.Conclusion:Sijunzi Decoction as the basic prescription in the treatment of ulcerative colitis can significantly improve the clinical efficacy，improve the expression of serum inflammatory mediators and superoxide dismutase,and has high safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
